Wall Street analysts forecast that Chipotle Mexican Grill (CMG) will report quarterly earnings of $0.24 per share in its upcoming release, pointing to a year-over-year decline of 4%. It is anticipated that revenues will amount to $2.98 billion, exhibiting an increase of 4.9% compared to the year-ago quarter.The consensus EPS estimate for the quarter has undergone an upward revision of 0.8% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reas ...

New York-based Pfizer Inc. (PFE) is a leading global biopharmaceutical company. With a market cap of $139.3 billion, it is focused on discovering, developing, and commercializing medicines and vaccines. Founded in 1849, Pfizer operates across multiple therapeutic areas, including oncology, vaccines, cardiology, immunology, rare diseases, and internal medicine. It is best known in recent years for its COVID-19 vaccine and antiviral treatment, developed in partnership with BioNTech. Shares of this pharmace ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Viewpoint - The stock market is expected to achieve another double-digit percentage gain in 2025, with the S&P 500 index showing a year-to-date gain of 16.81% as of December 5, despite significant declines in several individual stocks [1]. Group 1: Worst-Performing Stocks - Fiserv (FISV) has seen a decline of approximately 70%, attributed to a drastic cut in its full-year revenue forecast and slowing growth in its merchant-services segment [3]. - The Trade Desk (TTD) is down approximately 67%, facing decreased revenues due to competition from major players like Amazon, leading investors to view the stock as overvalued [4]. - Deckers Outdoor (DECK) has dropped around 57%, with slowing growth expectations and pressure on discretionary consumer spending impacting its well-known brands, UGG and Hoka [5]. - Gartner (IT) is down approximately 52%, with its valuation at $17 billion, facing cyclical pressure as companies reduce spending on advisory services during economic uncertainty [6].

Today, Dec. 16, 2025, Pfizer's shrinking COVID cash flows could mean little growth next year as M&A bets will take time to deliver. NYSE : PFEPfizerToday's Change( -3.40 %) $ -0.90Current Price$ 25.53Key Data PointsMarket Cap$150BDay's Range$ 24.92 - $ 26.5052wk Range$ 20.91 - $ 27.69Volume112MAvg Vol68MGross Margin69.12 %Dividend Yield6.51 %Pfizer (PFE 3.40%), which develops and sells biopharmaceutical products worldwide, closed today's session (Dec. 16) at $25.53, down 3.41%. Trading volume reached 108.1 ...

Core Viewpoint - Micron is expected to report significant growth in earnings and revenues for the upcoming quarter, indicating strong performance in the semiconductor industry [1]. Earnings and Revenue Estimates - Wall Street analysts predict Micron will post quarterly earnings of $3.84 per share, reflecting a 114.5% increase year-over-year [1]. - Revenues are forecasted to be $12.57 billion, representing a year-over-year increase of 44.3% [1]. - The consensus EPS estimate has been revised upward by 3.6% in the past 30 days, indicating a reassessment of initial estimates by analysts [2]. Revenue by Technology - Revenue from DRAM is projected to reach $10.13 billion, showing a year-over-year increase of 58.3% [5]. - Revenue from Other technologies (primarily NOR) is estimated at $82.40 million, reflecting a 21.2% year-over-year increase [5]. - NAND revenue is expected to be $2.34 billion, indicating a 4.2% year-over-year increase [5]. Stock Performance - Micron shares have increased by 9.1% over the past month, outperforming the Zacks S&P 500 composite, which moved up by 0.9% [6]. - With a Zacks Rank 1 (Strong Buy), Micron is anticipated to outperform the overall market in the near future [6].

Core Insights - IQVIA Holdings Inc. is valued at $37.6 billion and provides healthcare research services, including analytics, technology solutions, and clinical research to the life sciences industry, aimed at improving healthcare outcomes for patients [1] Performance Overview - Over the past year, IQV shares have gained 12.2%, underperforming the S&P 500 Index, which increased by nearly 13.7% [2] - In 2025, IQV's stock rose 10%, while the S&P 500 saw a 13.4% rise on a year-to-date basis [2] - Compared to the Health Care Select Sector SPDR Fund (XLV), which gained about 7% over the past year, IQV's performance is relatively better, although the ETF's 10.3% year-to-date returns outshine IQV's gains [3] Financial Results - For Q3, IQV reported an adjusted EPS of $3, exceeding Wall Street expectations of $2.96, and revenue of $4.10 billion, beating forecasts of $4.07 billion [4] - The company expects full-year adjusted EPS to be in the range of $11.85 to $11.95 and revenue between $16.2 billion and $16.3 billion [4] Analyst Expectations - Analysts project IQV's EPS to grow by 5.1% to $10.77 for the current fiscal year ending in December [5] - Among 22 analysts covering IQV, the consensus rating is a "Strong Buy," with 16 "Strong Buy" ratings, one "Moderate Buy," and five "Holds" [5] - A month ago, the bullish sentiment increased, with 15 analysts suggesting a "Strong Buy" [6] Price Targets - BMO Capital initiated coverage of IQV with an "Outperform" rating and a price target of $260, indicating a potential upside of 20.3% from current levels [6] - The mean price target is $244.38, representing a 13.1% premium to current prices, while the highest price target of $265 suggests an upside potential of 22.6% [6]

Core Insights - Charles River Laboratories International, Inc. (CRL) reported third-quarter 2025 adjusted earnings per share (EPS) of $2.43, a decrease of 6.2% year over year, but exceeded the Zacks Consensus Estimate by 4.74% [1][8] - The company’s total revenues for Q3 reached $1.00 billion, surpassing the Zacks Consensus Estimate by 2.06%, although this represented a 0.5% decline from the previous year [2][8] - CRL narrowed its 2025 revenue guidance following mixed segment results and margin contraction, now expecting total revenues to decline between 1.5% and 0.5% [9][10] Revenue Performance - Revenues from the Research Models and Services (RMS) segment totaled $213.5 million, reflecting a year-over-year increase of 7.9% [3] - The Discovery and Safety Assessment (DSA) segment reported revenues of $600.7 million, down 2.3% year over year, attributed to lower sales volume [4] - Manufacturing Solutions generated revenues of $190.7 million, a decrease of 3.1% year over year, primarily due to lower revenues in the CDMO and Biologics Testing businesses [5] Margin and Profitability - Gross profit for the quarter was $338.8 million, down 2.9% from the prior year, with a gross margin of 33.7%, which fell by 85 basis points [6] - Selling, general & administrative expenses decreased by 10.8% year over year to $177.6 million, while adjusted operating profit increased by 7.6% to $161.2 million, leading to an adjusted operating margin expansion of 121 basis points to 16% [6] Liquidity Position - At the end of Q3 2025, CRL had cash and cash equivalents of $207.1 million, an increase from $182.8 million at the end of Q2 [7] - Cumulative net cash provided by operating activities was $590.1 million, compared to $575.2 million a year ago [7] Future Outlook - The company expects adjusted EPS for 2025 to be in the range of $10.10-$10.30, slightly up from the previous estimate of $9.90-$10.30 [10] - Management noted stable demand across its portfolio of early-stage research and manufacturing products, indicating potential for recovery, though improvements may take time [12]

Group 1 - Merck & Co. has tightened its full-year revenue forecast to between $64.5 billion and $65 billion, up from a previous range of $64.3 billion to $65.3 billion [1] - Adjusted earnings per share are now expected to be between $8.93 and $8.98, an increase from the prior guidance of $8.87 to $8.97 [1] - The updated outlook reflects benefits from changes to the AstraZeneca collaboration, which eliminated a previous revenue- and cost-sharing arrangement [2] Group 2 - The company noted a reduction in tariff-related expenses due to President Trump's import tariff reforms and a more favorable tax rate outlook, partially offset by costs associated with the Verona acquisition [2] - Merck's acquisition of Verona Pharma, valued at approximately $10 billion, aims to expand its respiratory treatment portfolio and reduce reliance on the cancer drug Keytruda, whose patents are set to expire in 2028 [3] - In Q3, Merck reported a 3.7% year-over-year revenue increase to $17.28 billion, exceeding Bloomberg's consensus estimate, driven by growth in Keytruda sales despite weaker demand for the HPV vaccine Gardasil in China [3]

Core Viewpoint - FMC Corporation's stock plummeted 44% following a Q3 earnings report that showed a significant sales miss despite a slight earnings beat [1][8]. Financial Performance - Analysts had anticipated earnings of $0.86 per share and sales exceeding $1 billion, but FMC reported only $542 million in revenue, which is approximately half of the expected sales [1][3]. - Non-GAAP (adjusted) earnings were reported at $0.89 per share, but the GAAP results showed a substantial loss of $4.52 per share for the quarter [4][8]. Revenue Decline - Revenue fell 49% year-over-year, primarily due to significant one-time commercial actions in India related to the preparation for the sale of its India business. Without these actions, revenue would have been $961 million, reflecting only a 10% decline year-over-year [3][4]. Future Outlook - FMC has revised its 2025 revenue forecast to a range of $3.9 billion to $4 billion, representing a 7% decrease at the midpoint. The non-GAAP earnings range was also lowered to between $2.92 and $3.14, with an anticipated negative free cash flow of up to $200 million [6][8]. - The report is characterized as a "kitchen sink" approach, consolidating all negative news to potentially present a better outlook in future years, although 2025 is expected to be challenging [5][6].